Unternehmen / Aktien | News 24 h | News 7 T | Kurs | ||
---|---|---|---|---|---|
MODERNA | 11 | 54 | +0,32 % | ||
GILEAD SCIENCES | 9 | 18 | +0,09 % | ||
RENEO PHARMACEUTICALS | 7 | 7 | +0,91 % | ||
ATAI LIFE SCIENCES | 6 | 8 | +0,78 % | ||
BIONTECH | 5 | 27 | +0,19 % | ||
CENTESSA PHARMACEUTICALS | 4 | 4 | -6,60 % | ||
ACELYRIN | 4 | 4 | 0,00 % | ||
HUTCHMED | 3 | 9 | -0,68 % | ||
4D MOLECULAR THERAPEUTICS | 3 | 3 | -12,29 % | ||
REGENERON PHARMACEUTICALS | 2 | 17 | +0,45 % |
Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
Do | Genmab expands US headquarters, plots 300 hires amid launch of AbbVie-partnered lymphoma med Epkinly | 5 | FiercePharma | ||
Do | Centessa Pharmaceuticals GAAP EPS of -$0.38 | 1 | Seeking Alpha | ||
Do | Acelyrin GAAP EPS of -$5.43 | 1 | Seeking Alpha | ||
Do | Centessa Pharmaceuticals plc - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
Do | Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | 1 | GlobeNewswire (USA) | ||
Do | ATAI Life Sciences N.V. - 10-K, Annual Report | 1 | SEC Filings | ||
Do | ACELYRIN, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
Do | Blackstone Investing Up To $750 Million In Moderna | 6 | pulse2.com | ||
Do | Centessa Pharmaceuticals plc - 8-K, Current Report | 1 | SEC Filings | ||
Do | Centessa Pharmaceuticals plc: Centessa Pharmaceuticals Reports Business Highlights and Financial Results for the Fourth Quarter and Full-Year 2023 | 265 | GlobeNewswire (Europe) | Hemophilia Program: Ongoing registrational PRESent-2 and PRESent-3 studies of SerpinPC for the treatment of hemophilia B; PRESent-2 advancing toward interim analysis planned in 2024Orexin Agonist Program:... ► Artikel lesen | |
Do | Liquidia gains after court win in patent dispute with United Therapeutics | 2 | Seeking Alpha | ||
Do | Zymeworks Inc. - 8-K, Current Report | 1 | SEC Filings | ||
Do | Ardelyx, Inc. Reports Employment Inducement Grants | 1 | GlobeNewswire (USA) | ||
Do | Revolution Medicines, Inc.: Revolution Medicines to Deliver Multiple Presentations at the Upcoming American Association for Cancer Research Annual Meeting 2024 | 1 | GlobeNewswire (USA) | ||
Do | Enliven Therapeutics, Inc.: Enliven Therapeutics to Share Initial Proof of Concept Data from Phase 1 Clinical Trial of ELVN-001 and Host Virtual Key Opinion Leader Event on April 11, 2024 | 1 | GlobeNewswire (USA) | ||
Do | Galapagos NV: Galapagos publishes 2023 annual report and announces Annual and Extraordinary Shareholders' Meetings | 196 | GlobeNewswire (Europe) | Publication of annual report for financial year 2023Annual Shareholders' Meeting resolutions include approval of revised Remuneration Policy and (re)appointment of Board membersExtraordinary Shareholders'... ► Artikel lesen | |
Do | ACELYRIN, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
Do | Reneo Pharmaceuticals, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
Do | ACELYRIN, INC. Reports Full Year 2023 Financial Results and Recent Highlights | - | GlobeNewswire (USA) | ||
Do | Coherus BioSciences, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 3 | SEC Filings |